Article Details

Legend Biotech (NASDAQ:LEGN) Upgraded to Buy by Zacks Investment Research

Retrieved on: 2021-06-06 03:56:15

Tags for this article:

Click the tags to see associated articles and topics

Legend Biotech (NASDAQ:LEGN) Upgraded to Buy by Zacks Investment Research. View article details on hiswai:

Excerpt

Morgan Stanley reduced their target price on Legend Biotech from $55.00 to $50.00 and set an "overweight" rating on the stock in a research report on ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up